Rigin
- Category
- Specialized Research
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
Rigin is a synthetic tetrapeptide (Gly-Gln-Pro-Arg) sold as an immune modulator for phagocytosis, cytokine balance, and wound healing. The case rests mostly on mechanism and animal data, human evidence is low confidence, and claims of antimalarial or antifungal action are speculative. Human safety data is largely absent, with a theoretical risk of overstimulated immunity in autoimmune disease. Not FDA-approved; supply is unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(7)
Phagocytosis stimulation and innate immune enhancement
LowIn vitro and animal data show tuftsin-like phagocytic activity, no human studies conducted.
Cytokine modulation — IL-1, IL-6, and TNF regulation
SpeculativeIL-6 reduction claim comes from cosmetic industry data, no controlled studies confirm it.
Anti-inflammatory skin protection and collagen preservation
SpeculativeHuman studies used peptide blends only, individual contribution to skin protection unproven.
Evidence limits
- Evidence Level
- Preclinical
Rigin has a modest but growing evidence base. For systemic immunomodulatory applications, evidence is entirely preclinical: in vitro phagocytosis assays, cytokine modulation studies in mouse macrophages and human monocytes, and in vivo malaria protection studies in mice. No clinical trials have evaluated systemic rigin administration in humans. For topical anti-aging use, palmitoyl tetrapeptide-7 has been tested in several small clinical studies as part of multi-ingredient formulations, showing reductions in wrinkles, improvements in elasticity, and increases in dermal density and collagen. However, no placebo-controlled RCT has isolated palmitoyl tetrapeptide-7 as the sole active ingredient. Safety data is favorable: HRIPT in 52 subjects showed no irritation or sensitization, and clinical studies report no adverse reactions at standard cosmetic concentrations (0.01-2%).
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Unknown systemic safety profile
HighLimited long-term topical safety data
ModerateContact dermatitis (topical palmitoyl tetrapeptide-7)
LowSkin irritation when combined with retinoids
TheoreticalPotential immunostimulatory risk in autoimmune conditions
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.